Based on the key measurements obtained from Vir Biotechnology's financial statements, Vir Biotechnology is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Vir Biotechnology's Short Term Investments are relatively stable compared to the past year. As of 11/29/2024, Capital Surpluse is likely to grow to about 1.9 B, while Total Stockholder Equity is likely to drop slightly above 941.7 M. Key indicators impacting Vir Biotechnology's financial strength include:
The essential information of the day-to-day investment outlook for Vir Biotechnology includes many different criteria found on its balance sheet. An individual investor should monitor Vir Biotechnology's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Vir Biotechnology.
Net Income
(584.31 Million)
Vir
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Revenue Per Share
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Investments
Change In Cash
Net Borrowings
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Cash And Cash Equivalents Changes
Total Cash From Operating Activities
Cash Flows Other Operating
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Common Stock Total Equity
Retained Earnings Total Equity
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Surpluse
Capital Lease Obligations
Other Current Assets
Other Stockholder Equity
Total Liab
Deferred Long Term Liab
Net Invested Capital
Long Term Investments
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Non Current Liabilities Other
Net Working Capital
Short Term Debt
Intangible Assets
Common Stock
Property Plant Equipment
Current Deferred Revenue
Capital Stock
Short Long Term Debt Total
Net Receivables
Tax Provision
Net Interest Income
Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Non Operating Income Net Other
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Probability Of Bankruptcy
Understanding current and past Vir Biotechnology Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Vir Biotechnology's financial statements are interrelated, with each one affecting the others. For example, an increase in Vir Biotechnology's assets may result in an increase in income on the income statement.
Vir Biotechnology competes with CureVac NV, Krystal Biotech, Blueprint Medicines, Amylyx Pharmaceuticals, and Day One. Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California. Vir Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 444 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Vir Biotechnology's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Vir Biotechnology's current stock value. Our valuation model uses many indicators to compare Vir Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vir Biotechnology competition to find correlations between indicators driving Vir Biotechnology's intrinsic value. More Info.
Vir Biotechnology is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Vir Biotechnology's Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Vir Biotechnology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Vir Biotechnology Systematic Risk
Vir Biotechnology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Vir Biotechnology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Vir Biotechnology correlated with the market. If Beta is less than 0 Vir Biotechnology generally moves in the opposite direction as compared to the market. If Vir Biotechnology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Vir Biotechnology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Vir Biotechnology is generally in the same direction as the market. If Beta > 1 Vir Biotechnology moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Vir Biotechnology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vir Biotechnology's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Vir Biotechnology growth as a starting point in their analysis.
Vir Biotechnology November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Vir Biotechnology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Vir Biotechnology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Vir Biotechnology based on widely used predictive technical indicators. In general, we focus on analyzing Vir Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Vir Biotechnology's daily price indicators and compare them against related drivers.
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.